Clinical trials: Chronic Obstructive Pulmonary Disease Severe
COPD, COPD Exacerbation
AIRVO Device Intervention for Moderate to Severe COPD
This is an open (non-blinded), single-arm, clinical trial to assess the efficacy of daily use of a high-flow nasal cannula (HFNC) device in patients with moderate to severe COPD, in addition to standard care, in reducing the…
- Trial name
- AIRVO (NCT04576936)
- Testing
- AIRVO
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Renown Health
COPD
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01636401
- Testing
- aclidinium bromide 400 μg
- Where
- South Korea
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Asthma, Chronic Obstructive Pulmonary Disease
Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease
This clinical trial will include healthy volunteers, COPD patients and asthmatic patients who will breathe He/O2 78:22, He/O2 65:35 and medical air consecutively in a randomised order.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Healthy
- Trial name
- NCT00801307
- Testing
- spirometer
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Air Liquide SA
Chronic Obstructive Pulmonary Disease
Quality of Life in Daxas-treated Patients Older Than 18 Years With Severe Chronic Obstructive Pulmonary Disease (COPD) (DACOTA)
Chronic obstructive pulmonary disease (COPD) is a progressive and largely irreversible lung disease characterized by chronic bronchitis and/or emphysema, resulting in breathlessness, cough and sputum.
- Trial name
- DACOTA (NCT01285167)
- Testing
- Daxas
- Where
- 605 sites in Germany
- Volunteers
- 3,645 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Severe Early-Onset
COPD Readmissions Prediction- ReCOPD Project
To develop predictive models for short-term readmission (60 days) and medium term (one year) for patients with an exacerbation of COPD (eCOPD) which are admitted to any of the participant hospitals.
- Trial name
- ReCOPD (NCT03227211)
- Where
- 8 sites in Spain
- Volunteers
- 1,500 people
- Sponsor
- Hospital Galdakao-Usansolo
COPD
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01009424
- Testing
- R7103
- Sponsor
- Hoffmann-La Roche
Emphysema, Pulmonary, Emphysema or COPD
An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) in the target lobe.
- Trial name
- CONVERT_II (NCT06035120)
- Testing
- AeriSeal System
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 200 people
- Sponsor
- Pulmonx Corporation
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD
The aim of this study is to compare the effectiveness of two treatments for severe / very severe COPD patients: one, conventional medicine based on 2013 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese…
- Trial name
- NCT02270424
- Testing
- Salmeterol / fluticasone (Seretide®), Bufeijianpi granule, Bufeiyishen granule
- Volunteers
- 564 people
- Sponsor
- Henan University of Traditional Chinese Medicine
COPD
Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD
The aim of the current study is to compare the efficacy and safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder treatment administered via Capsair twice daily and original product Seretide Diskus 500 mcg Inhalation…
- Trial name
- COPD (NCT03363503)
- Testing
- Salmeterol/Fluticasone Capsair®, Salmeterol/Fluticasone Diskus®
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Severe Chronic Obstructive Pulmonary Disease, Dyspnea
The Effectiveness Pulmonary Telerehabilitation and Cognitive Telerehabilitation in COPD Patients
The aim of our study is to compare the effectiveness of the supervized pulmonary telerehabilitation program and the cognitive telerehabilitation method, which includes pulmonary telerehabilitation methods, in patients with severe…
- Conditions
- Severe Chronic Obstructive Pulmonary Disease, Dyspnea, Muscle Weakness, Fatigue
- Trial name
- NCT05222295
- Testing
- Supervised Pulmonary Telerehabilitation, Cognitive Telerehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Saglik Bilimleri Universitesi
Severe Emphysema
A Multi-center RCT to Evaluate Subsegmental BTVA Treatment for Severe Emphysema
To compare the efficacy and safety of subsegmental treatment and segmental treatment with InterVapor in patients with severe emphysema
- Trial name
- BTVA (NCT06152107)
- Testing
- BTVA treatment plus optimal medical therapy (GOLD guidelines)
- Where
- 9 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Pulmonary Hypertension, Chronic Obstructive Lung Disease
Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post BLVR
This study is designed as a prospective study, with the primary endpoint being changes in pulmonary hemodynamic parameters after ELVR in patients with severe emphysema.
- Trial name
- NCT02778802
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Cairo University
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD.
- Trial name
- PT009001 (NCT02196077)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BFF MDI 80/9.6 μg
- Where
- 17 sites in United States
- Volunteers
- 180 people
- Sponsor
- Pearl Therapeutics, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The aim of the present study is to evaluate the 24h bronchodilatory efficacy of inhaled aclidinium bromide 400 µg administered twice a day versus placebo and tiotropium bromide, respectively, after 6 weeks of treatment.
- Trial name
- NCT01462929
- Testing
- Aclidinium bromide, Tiotropium
- Where
- 41 sites in Czechia, Germany and 2 more
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Chronic Obstructive Airways Disease Exacerbated, Chronic Obstructive Airway Disease
Digital Inhaler Use in Obstructive Lung Disease Care
This is a pilot study to evaluate the role digital inhaler technology on patients with obstructive lung disease in preventing admissions and exacerbation, as well as improving symptom control.
- Trial name
- NCT07214337
- Testing
- Digital Inhaler Attachment
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cedars-Sinai Medical Center
Chronic Obstructive Pulmonary Disease Severe
Cell Therapy Associated With Endobronchial Valve
Chronic obstructive pulmonary disease (COPD) is one of the most common diseases worldwide and is considered a public health problem. The World Health Organization estimates that about 210 million people have COPD.
- Trial name
- CEL&VAL (NCT04018729)
- Testing
- Zephyr Endobronchial Valve, Marrow-derived mesenchymal stromal cell
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
RSV
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Zelicapavir is a novel orally administered non-fusion replication inhibitor of RSV that is being developed for the treatment of patients with RSV infection.
- Trial name
- RESOLVE (NCT07908381)
- Testing
- zelicapavir
- Where
- 4 sites in United States
- Volunteers
- 860 people
- Sponsor
- Enanta Pharmaceuticals, Inc
Severe Eosinophilic Asthma
Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma
Understanding how Interleukin-5 blockade modulates both immune and metabolic pathways may clarify the multidimensional impact of biologic therapy in severe eosinophilic asthma.
- Trial name
- NCT05063981
- Testing
- Mepolizumab
- Where
- 2 sites in Italy
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Istituti Clinici Scientifici Maugeri SpA
COPD, Chronic Obstructive Pulmonary Disease
Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD
The clinical objectives of this study are to determine whether utilization of the Wellinks COPD Solution can improve quality of life for patients with COPD, can reduce healthcare resource utilization over time, and can improve…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
- Trial name
- ASPIRE (NCT05259280)
- Testing
- Wellinks
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- Convexity Scientific Inc